Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile

A method of rapidly treating migraine in a human, the method comprising delivering to the human a total dose of less than 3.0 mg of dihydroergotamine mesylate to provide a mean peak plasma concentration (Cmax) of dihydroergotamine that is less than 15,000 pg/ml within a mean time to Cmax (Tmax) that is less than 20 minutes after the delivery;

• wherein the delivering is via pulmonary administration by oral inhalation using a breath actuated pressurized metered dose inhaler (pMDI);
• wherein the pMDI contains a suspension of the dihydroergotamine mesylate in a hydrofluoroalkane (HFA) propellant blend;
• wherein the propellant blend consists of HFA 227ea (1,1,1,2,3,3,3-heptafluoropropane) and HFA 134a (1,1,1,2-tetrafluoroethane);
• thereby providing rapid relief of the migraine in the human.